The Dry Eye Zone

Rebecca's Blog

-

Coming soon to an ECP near you: Cheaper Lipiflow?

Seems probable...

TearScience® Announces New Pricing Strategy For Core LipiFlow®Technology Used For Treatment Of Dry Eye From Meibomian Gland Disease (MGD)


MORRISVILLE, N.C.--10/28/15 - ()--TearScience, a privately held medical device company, has announced a 50% price cut, effective immediately, on the single-use activators used with the LipiFlow treatment platform for Meibomian Gland Disease (MGD). The move is just one component of an overall strategy to make the LipiFlow and LipiView® Technologies more accessible to Eye Care Professionals (ECPs), who can then, in turn, use them to evaluate and intervene earlier in MGD for the benefit of the millions of individuals suffering from this chronic and progressive obstructive gland disease.

After recent unprecedented growth in use of its LipiFlow technology, TearScience is achieving the economies of scale necessary to reorganize and expand its supply and manufacturing capabilities. Furthermore, TearScience brought on board a new management team with a renewed mission to meet a market need of technology and treatment accessibility. Earlier this year, TearScience lowered the price of its technologies and removed imaging fees....

Rebecca2 Comments